Global CAR T Cell Therapy Market to Showcase 40% CAGR in Next Six Years

Posted On October 09, 2018

Value Market Research reveals its latest publication on the Global CAR T Cell Therapy Market which offers the forecast of the market size from 2017 to 2024. This study demonstrates that the global CAR T cell therapy market was valued USD 150 MN (by revenue) in 2017 and is anticipated to reach USD 1,581.2 MN by 2024 with a CAGR of 40%. The prime objective of this report is to provide a detailed analysis of the key market trend along with the current and future industry scenario.

Car T- cell therapy uses the immune system to help fight against cancer cells. Basically, CARs are made up of an antibody-derived fragment that recognizes tumor antigens attached to costimulatory molecules that promote T cell expansion and persistence. Car T- cell therapy is done by collecting blood via a process called apheresis or leukapheresis. In this process T-cells are separated from rest of the blood, then the extracted T-cells are engineered specifically to attack B-cell lymphoma cells. After which, the engineered T-cells multiplied and given to the cancer patient through an IV infusion. Car T- cell is a complex treatment and can cause severe side effects sometimes.  

The report - "Global CAR T Cell Therapy Market Report By Targeted Antigen (CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, Egfrvlll And Others), By Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblastoma, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular, Carcinoma, Colorectal Cancer And Others) And By Regions - Industry Trends, Size, Share, Growth, Estimation, And Forecast, 2017-2024"evaluates the present scenario and the growth prospects of the regional market.Further, the report describes the segmentation based on the targeted antigen, therapeutic application, and region.

Download the FREE SAMPLE of Global CAR T Cell Therapy Market Research Report


Car T-cells therapy has emerged as a potent and viable therapeutic intervention to remove the cancer cells with fewer side-effects. Rising number of cancer patients showing negative response towards other alternative treatment followed by increasing government initiatives for promoting research for cell therapy is fueling the industry expansion. Furthermore, rising number of global players collaborating and signing research as well as manufacturing agreement for CAR-T cell therapies with local players is again expected to foster the market growth. Also, expanding biotechnology and life science sector coupled with the advancement in the cell therapy and gene therapy has supported the market growth immensely.
 
Target antigen is further categorized into CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, Egfrvlll, and others. CD 19 is currently leading the segment owing to its efficacy in the treatment of acute lymphoblastic leukemia. Also, rising cases of acute lymphoblastic leukemia among the population have raised its demand to be utilized for cancer therapy. The therapeutic application covers acute lymphocytic leukemia, chronic lymphocytic leukemia, non-hodgkin leukemia, multiple myeloma, pancreatic cancer, neuroblastoma, breast cancer, acute myeloid leukemia, hepatocellular, carcinoma, colorectal cancer and others. Among which, acute lymphocytic leukemia is dominating the segment owing to the continuous growing cases of cancer among children and adults.

Regional segmentation covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is ruling the global CAR T cell therapy market owing to a large number of patients suffering from cancer in the U.S. and Canada. Also, increasing investment in research for the development of cancer therapies is again expected to stimulate the market growth in the region.

The Report Segments Global CAR T Cell Therapy Market -
By Target Antigen

  • CD 19
  • CD 20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • HER2
  • Meso
  • Egfrvlll
  • Others 

By Therapeutic Application

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Leukemia
  • Multiple Myeloma
  • Pancreatic Cancer
  • Neuroblasta
  • Breast Cancer
  • Acute Myeloid Leukemia
  • Hepatocellular
  • Carcinoma
  • Colorectal Cancer
  • Others 

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Vendors Highlighted In The Report:
Bellicum Pharmaceuticals, Inc., Celgene Corporation, Cellectis, Juno Therapeutics, Kite Pharma Inc., Novartis International AG and Sorrento Therapeutics, Inc.

PURCHASE Complete Global CAR T Cell Therapy Market Research Report

 
About Value Market Research -
Value Market Research was established with the vision to ease decision making and empower the strategists by providing them with holistic market information. Our analysts’ team is well equipped with all research tools and techniques and hold deep knowledge of the industry they are working for.

We ensure intellectual, precise and quality data is delivered to our client. We facilitate clients with syndicate research reports and customized research reports on 25+ industries with global as well as regional coverage.

Contact:
Value Market Research
401/402, TFM, Nagras Road, Aundh, Pune-7.
Maharashtra, INDIA.
Tel: +1-888-294-1147
Email: [email protected]
Website: https://www.valuemarketresearch.com